期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 15, 期 9, 页码 1293-1306出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2015.1051528
关键词
clinical application; cryopreservation; human umbilical cord mesenchymal stem cells; isolation; paracrine
资金
- Beike Biotech
- National Science Foundation of China [81230026, 81171085]
Introduction: Human umbilical cord mesenchynnal stem cells (HUC-MSCs) are one of the typical adult stem cells; they have superiorities including low immunogenicity, non-invasive harvest procedure, easy expansion in vitro, and ethical access compared with stem cells from other sources. Therefore, HUC-MSCs are a promising candidate for cell-based therapy. Areas covered: Here we reviewed the development of stem cell-based therapy, the manufacturing and banking process of HUC-MSCs, the emerging clinical studies in the field of cancer, central nervous system diseases, liver diseases and graft-versus-host disease, the potential therapeutic mechanisms, as well as challenges of HUC-MSCs in clinical translation. Expert opinion: HUC-MSCs seem to be an optimal choice for stem cell-based therapy. However, before the cells translate from basic to clinical research, some problems still remain to be solved: i) building regulatory guidelines as well as an efficient and safe manufacturing procedure; ii) establishing donor's genetic testing and long-term closely monitoring system; iii) conducting further clinical trials to determine the optimum and standard dosage, time, route, frequency and many other technical issues of HUC-MSCs transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据